CLRB Cellectar Biosciences, Inc.
1.510USD0.00%Mkt Cap: 14.27M $P/E: —1d ago
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid d…
Industry Peers
Biotechnology$128.08BUSDP/E 29.4
$78.44BUSD
$76.40BUSDP/E 18.4
$57.03BUSDP/E 37.3
$58.08BUSDP/E 35.4
$42.24BUSDP/E 18.0
$43.05BUSD
$41.41BUSDP/E 65.1
$32.80BUSDP/E 30.2
$30.03BUSDP/E 37.8
$25.10BUSD
$23.93BUSD
$22.27BUSDP/E 30.7
$22.99BUSDP/E 14.5
$22.54BUSDP/E 28.9
$22.22BUSD
$15.03BUSDP/E 17.5
$15.01BUSDP/E 15.8
$14.48BUSDP/E 18.4
$14.32BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript Phase 3 trial underway for iopofosine I 131 in Waldenstrom's macroglobulinemia. | ||
Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ... Company reports 79.2% major response rate in high-risk WM patients and secures up to $140 million to support NDA submission and pipeline expansion. | ||
 Cellectar Biosciences, Inc. Q2 2026 Earnings Call Summary Moby summary of Cellectar Biosciences, Inc.'s Q2 2026 earnings call | ||